Aim To determine the characteristics of KRAS, NRAS, BRAF, PIK3CA gene mutation and loss of PTEN expression in colorectal adenocarcinoma in Can Tho Oncology Hospital. Materials and methods A cross-sectional study included 50 cases of colorectal adenocarcinoma were diagnosed and treated at Can Tho Oncology Hospital. KRAS, NRAS, BRAF, PIK3CA mutations identified by Sanger DNA sequencing as well as evaluating the loss of PTEN protein expressed by MHC. Results and discussion Among the 50 colorectal cancer patients, we detected 17 (34%) mutations in the KRAS, NRAS (0%), BRAF 1(2%) and PIK3CA 3(6%), all of which were point mutations. Mutation frequencies at codon 12 and codon 13 were 26%. Only one patient harboured a point mutation at codon 10. Th...
Stage I colorectal carcinoma has excellent prognosis, with 5-year survival rate up to 95%. The occur...
Introduction: Colorectal cancer (CRC) arises from the cumulative effects of genetic and epigenetic a...
Mutations in KRAS oncogene are recognized biomarkers that predict lack of response to anti- epiderma...
To investigate the frequency and relationship of the KRAS, BRAF and PIK3CA mutations and the loss of...
Molecular alterations in KRAS, BRAF, PIK3CA, and PTEN have been implicated in designing targeted the...
<div><h3>Background</h3><p>To investigate the frequency and relationship of the <em>KRAS</em>, <em>B...
Activation of KRAS oncogene is responsible for the transition from intermediate adenoma to carcinoma...
Mutations in PIK3CA are present in 10 to 15% of colorectal carcinomas. We aimed to examine how PIK3C...
Mutations in PIK3CA are present in 10 to 15 % of colorectal carcinomas. We aimed to examine how PIK3...
Mutations in PIK3CA are present in 10 to 15% of colorectal carcinomas. We aimed to examine how PIK3C...
Purpose: PIK3CA and PTEN mutations are prevalent in colorectal cancer and potential markers of respo...
KRAS, NRAS and BRAF are kinases involved in the RAS-RAF-MAPK signaling pathway and also potential tu...
To identify the mutation rate of KRAS and BRAF in Chinese patients with colorectal carcinoma (CRC), ...
Abstract. Tumour suppressor gene, PTEN has been found to be altered in various types of tumours such...
Mutations in KRAS oncogene are recognized biomarkers that predict lack of response to anti- epiderma...
Stage I colorectal carcinoma has excellent prognosis, with 5-year survival rate up to 95%. The occur...
Introduction: Colorectal cancer (CRC) arises from the cumulative effects of genetic and epigenetic a...
Mutations in KRAS oncogene are recognized biomarkers that predict lack of response to anti- epiderma...
To investigate the frequency and relationship of the KRAS, BRAF and PIK3CA mutations and the loss of...
Molecular alterations in KRAS, BRAF, PIK3CA, and PTEN have been implicated in designing targeted the...
<div><h3>Background</h3><p>To investigate the frequency and relationship of the <em>KRAS</em>, <em>B...
Activation of KRAS oncogene is responsible for the transition from intermediate adenoma to carcinoma...
Mutations in PIK3CA are present in 10 to 15% of colorectal carcinomas. We aimed to examine how PIK3C...
Mutations in PIK3CA are present in 10 to 15 % of colorectal carcinomas. We aimed to examine how PIK3...
Mutations in PIK3CA are present in 10 to 15% of colorectal carcinomas. We aimed to examine how PIK3C...
Purpose: PIK3CA and PTEN mutations are prevalent in colorectal cancer and potential markers of respo...
KRAS, NRAS and BRAF are kinases involved in the RAS-RAF-MAPK signaling pathway and also potential tu...
To identify the mutation rate of KRAS and BRAF in Chinese patients with colorectal carcinoma (CRC), ...
Abstract. Tumour suppressor gene, PTEN has been found to be altered in various types of tumours such...
Mutations in KRAS oncogene are recognized biomarkers that predict lack of response to anti- epiderma...
Stage I colorectal carcinoma has excellent prognosis, with 5-year survival rate up to 95%. The occur...
Introduction: Colorectal cancer (CRC) arises from the cumulative effects of genetic and epigenetic a...
Mutations in KRAS oncogene are recognized biomarkers that predict lack of response to anti- epiderma...